These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1262 related articles for article (PubMed ID: 29490706)

  • 1. Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer's disease.
    Sosna J; Philipp S; Albay R; Reyes-Ruiz JM; Baglietto-Vargas D; LaFerla FM; Glabe CG
    Mol Neurodegener; 2018 Mar; 13(1):11. PubMed ID: 29490706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microglia depletion rapidly and reversibly alters amyloid pathology by modification of plaque compaction and morphologies.
    Casali BT; MacPherson KP; Reed-Geaghan EG; Landreth GE
    Neurobiol Dis; 2020 Aug; 142():104956. PubMed ID: 32479996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-β pathology.
    Spangenberg EE; Lee RJ; Najafi AR; Rice RA; Elmore MR; Blurton-Jones M; West BL; Green KN
    Brain; 2016 Apr; 139(Pt 4):1265-81. PubMed ID: 26921617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Colony-Stimulating Factor 1 Receptor by PLX3397 Prevents Amyloid Beta Pathology and Rescues Dopaminergic Signaling in Aging 5xFAD Mice.
    Son Y; Jeong YJ; Shin NR; Oh SJ; Nam KR; Choi HD; Choi JY; Lee HJ
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32756440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice.
    Dagher NN; Najafi AR; Kayala KM; Elmore MR; White TE; Medeiros R; West BL; Green KN
    J Neuroinflammation; 2015 Aug; 12():139. PubMed ID: 26232154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of microglial depletion and TREM2 deficiency on Aβ plaque burden and neuritic plaque tau pathology in 5XFAD mice.
    Delizannis AT; Nonneman A; Tsering W; De Bondt A; Van den Wyngaert I; Zhang B; Meymand E; Olufemi MF; Koivula P; Maimaiti S; Trojanowski JQ; Lee VM; Brunden KR
    Acta Neuropathol Commun; 2021 Sep; 9(1):150. PubMed ID: 34503586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microglia contributes to plaque growth by cell death due to uptake of amyloid β in the brain of Alzheimer's disease mouse model.
    Baik SH; Kang S; Son SM; Mook-Jung I
    Glia; 2016 Dec; 64(12):2274-2290. PubMed ID: 27658617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Aβ antibodies bound to neuritic plaques enhance microglia activity and mitigate tau pathology.
    Laversenne V; Nazeeruddin S; Källstig EC; Colin P; Voize C; Schneider BL
    Acta Neuropathol Commun; 2020 Nov; 8(1):198. PubMed ID: 33225991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trem2 Deletion Reduces Late-Stage Amyloid Plaque Accumulation, Elevates the Aβ42:Aβ40 Ratio, and Exacerbates Axonal Dystrophy and Dendritic Spine Loss in the PS2APP Alzheimer's Mouse Model.
    Meilandt WJ; Ngu H; Gogineni A; Lalehzadeh G; Lee SH; Srinivasan K; Imperio J; Wu T; Weber M; Kruse AJ; Stark KL; Chan P; Kwong M; Modrusan Z; Friedman BA; Elstrott J; Foreman O; Easton A; Sheng M; Hansen DV
    J Neurosci; 2020 Feb; 40(9):1956-1974. PubMed ID: 31980586
    [No Abstract]   [Full Text] [Related]  

  • 10. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation.
    Oakley H; Cole SL; Logan S; Maus E; Shao P; Craft J; Guillozet-Bongaarts A; Ohno M; Disterhoft J; Van Eldik L; Berry R; Vassar R
    J Neurosci; 2006 Oct; 26(40):10129-40. PubMed ID: 17021169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF1R inhibition rescues tau pathology and neurodegeneration in an A/T/N model with combined AD pathologies, while preserving plaque associated microglia.
    Lodder C; Scheyltjens I; Stancu IC; Botella Lucena P; Gutiérrez de Ravé M; Vanherle S; Vanmierlo T; Cremers N; Vanrusselt H; Brône B; Hanseeuw B; Octave JN; Bottelbergs A; Movahedi K; Dewachter I
    Acta Neuropathol Commun; 2021 Jun; 9(1):108. PubMed ID: 34103079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective targeting and modulation of plaque associated microglia via systemic hydroxyl dendrimer administration in an Alzheimer's disease mouse model.
    Henningfield CM; Soni N; Lee RW; Sharma R; Cleland JL; Green KN
    Alzheimers Res Ther; 2024 May; 16(1):101. PubMed ID: 38711159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology.
    Olmos-Alonso A; Schetters ST; Sri S; Askew K; Mancuso R; Vargas-Caballero M; Holscher C; Perry VH; Gomez-Nicola D
    Brain; 2016 Mar; 139(Pt 3):891-907. PubMed ID: 26747862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer's disease.
    Puntambekar SS; Moutinho M; Lin PB; Jadhav V; Tumbleson-Brink D; Balaji A; Benito MA; Xu G; Oblak A; Lasagna-Reeves CA; Landreth GE; Lamb BT
    Mol Neurodegener; 2022 Jun; 17(1):47. PubMed ID: 35764973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques.
    Pensalfini A; Albay R; Rasool S; Wu JW; Hatami A; Arai H; Margol L; Milton S; Poon WW; Corrada MM; Kawas CH; Glabe CG
    Neurobiol Dis; 2014 Nov; 71():53-61. PubMed ID: 25092575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alzheimer disease: cellular and molecular aspects].
    Octave JN
    Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model.
    Spangenberg E; Severson PL; Hohsfield LA; Crapser J; Zhang J; Burton EA; Zhang Y; Spevak W; Lin J; Phan NY; Habets G; Rymar A; Tsang G; Walters J; Nespi M; Singh P; Broome S; Ibrahim P; Zhang C; Bollag G; West BL; Green KN
    Nat Commun; 2019 Aug; 10(1):3758. PubMed ID: 31434879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brimapitide Reduced Neuronal Stress Markers and Cognitive Deficits in 5XFAD Transgenic Mice.
    Gourmaud S; Thomas P; Thomasseau S; Tible M; Abadie C; Paquet C; Hugon J
    J Alzheimers Dis; 2018; 63(2):665-674. PubMed ID: 29660941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial reduction of microglia does not affect tau pathology in aged mice.
    Bennett RE; Bryant A; Hu M; Robbins AB; Hopp SC; Hyman BT
    J Neuroinflammation; 2018 Nov; 15(1):311. PubMed ID: 30413160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer's disease.
    Brunner D; Flunkert S; Neddens J; Duller S; Scopes DIC; Treherne JM; Hutter-Paier B
    Neurosci Lett; 2017 Nov; 660():96-102. PubMed ID: 28917978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.